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Biological small-molecule-dependent switches sense
external chemical signals and transduce them into
appropriate internal signals and cellular responses.
Artificial molecular switches that control the function
of any protein of interest using a small molecule are
powerful tools for studying biology because they en-
able cellular responses to be controlled by inputs
chosen by researcher. Furthermore, these switches
can combine the generality of genetic regulation with
the reversibility and temporal control afforded by
small molecules. Three approaches to creating mo-
lecular switches include altering a natural switch to
recognize new exogenous ligands, engineering no-
vel allosteric responses to ligand binding, or enforc-
ing protein localization with chemical dimerizers.
Here, we discuss the development of small-molecule-
dependent switches that control in a general fashion
transcriptional activation, translational initiation, and
protein activity posttranslationally.
Introduction
A defining characteristic of life is the ability to sense
changes in the environment and react appropriately.
Cells must respond to a dizzying array of stimuli, in-
cluding nutrient gradients, chemical signals, temper-
ature, mechanical stress, light, and sound. Nature has
accordingly evolved complex systems that monitor the
environment and rapidly alter gene expression and pro-
tein activity in response to changing conditions.
Regulation of the E. coli lac operon, elucidated in
1961 by Jacob and Monod [1], was the first well-char-
acterized example of a genetic response to a chemical
signal. Fluctuations in the amount of available nutrients
require that bacteria rapidly switch between metaboliz-
ing different substrates, but the synthesis of high levels
of nonessential enzymes is energetically costly. In the
absence of lactose, E. coli cells repress lacZYA expres-
sion such that there are fewer than five copies of the
LacZ protein per cell; 10 min after induction with lac-
tose, there can be w5000 copies per cell. This regula-
tion is accomplished by the repressor LacI, which binds
to the DNA sequence (the “operator”) upstream of the
lacZYA genes and blocks RNA polymerase from initiat-
ing transcription. Upon binding the inducer allolactose,
LacI undergoes a conformational change that lowers
its affinity for the operator DNA, dissociating the re-*Correspondence: drliu@fas.harvard.edupressor-DNA complex and permitting transcription and
translation of lacZYA.
Specialized sensing molecules such as LacI act as
molecular switches and lie at the heart of biological
responses to stimuli. They play the crucial role of re-
cognizing an external signal and transducing it into a
relevant functional output. In many cases, secondary
switches relay cellular signals in a cascade of signal
transduction events mediated by protein phosphoryla-
tion. This review, however, focuses on small-molecule
inputs and will use the term “molecular switch” to refer
to biological macromolecules (RNA or protein) that ef-
fect small-molecule-dependent changes in the expres-
sion level or activity of a protein. Furthermore, we will
focus on switches that display generality: the ability to
regulate expression or protein function in a manner that
does not depend on any specific property of the target
protein.
In addition to their central role in biology, molecular
switches have proven to be important tools for analyz-
ing biological systems. In this context, switches acti-
vated by small molecules offer significant advantages
over switches regulated by other inputs. Many small
molecules diffuse freely across cell membranes and
can be added to a culture of cells or injected into an
organism, enabling precise temporal and spatial con-
trol. In contrast to classical genetic approaches that in-
troduce changes at the DNA level, chemical effectors
can act reversibly, rapidly, and yield a dose-dependent
response in which modulating the concentration of the
effector can result in a proportional change in activity.
The major challenge of using small molecules alone
to perturb protein function is the need to synthesize
and identify a different small-molecule effector for ev-
ery protein of interest. In addition, some molecules that
bind a target with high affinity can also bind other pro-
teins in vivo, complicating the interpretation of these
studies. If nontarget proteins with modest affinity for a
small molecule are more abundant or accessible than
the desired target, side effects and loss of ligand po-
tency can result. While researchers screening combina-
torial libraries of small molecules have succeeded in
targeting numerous proteins of interest, the discovery
of a specific chemical inhibitor for every protein in a
cell remains an outstanding challenge.
In contrast, genetic approaches offer both the gener-
ality to target any gene of interest and the specificity
for one and only one gene. These desirable features
arise from the precision of genetic techniques that alter
the DNA sequence encoding a protein of interest. Bal-
ancing these advantages, however, are the difficulties
of genetic manipulation in higher organisms, the fact
that alterations at the genomic level are nonreversible,
and the potential cellular lethality of genetic changes
to essential genes. Although the use of conditional tem-
perature-dependent alleles overcomes some of these
difficulties, the mechanism of temperature dependence
is often uncertain, and temperature shifts themselves
can exert confounding effects on a biological system [2].
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by small molecules can combine some of the advan-
tages of genetic and chemical approaches. Small-mole-
cule control of the switch offers temporal and spatial
precision. Moreover, since the switch is expressed in
vivo and acts only on the gene of interest, downstream
functions can be regulated with high specificity. These
advantages, however, typically come at the expense of
slower kinetics than approaches that rely solely on
small molecules, and genetic intervention is still re-
quired. Because natural switches do not possess the
generality and independence from cellular systems that
are necessary for their application, artificial molecular
switches must be created to exploit the above advan-
tages.
Essential Features of Molecular Switches
As defined above, molecular switches must bind at
least two molecules: the small-molecule effector and
the downstream target. The LacI protein, for example,
binds to the small-molecule inducer isopropyl-β-D-thio-
galactopyranoside (IPTG) with a w1 M dissociation
constant and to the DNA of the operator site with Kd =
10−13 M. Not only must these interactions be of high
affinity, but they must also be highly specific: LacI binds
the inducer allolactose but does not bind other sugars
F
Tdiffering only in the stereochemical configuration at a
[
single carbon atom. Likewise, LacI recognizes the ten s
base pair lac operator sequence amidst a vast excess (
lof noncognate genomic DNA.
bJacques Monod emphasized a key property of mo-
slecular switches: they bind molecules that have no nec-
tessary chemical relation to one another [3]. The func-
tional relationship between the two binding sites is
provided by the switch itself. One approach to engi- g
dneering artificial molecular switches is therefore to re-
design ligand-receptor interfaces so that downstream o
[function is controlled by small-molecule inputs chosen
by the researcher (Figure 1). Analogs of natural small- t
cmolecule ligands can avoid interference with other cel-
lular processes. Even greater control over a system can a
bbe gained by engineering an orthogonal receptor that
responds only to the exogenous ligand. Together, a t
csynthetic ligand and altered receptor constitute an or-
thogonal pair. r
lIn addition to binding a small molecule tightly and
specifically, a molecular switch must also convert the a
binding of the allosteric effector into an altered func-
tional output. A current model of protein structure, s
abased on NMR studies of folding dynamics, postulates
a collection of conformational states in which some re- t
lgions of the protein are disordered due to local unfold-
ing [4]. According to this model, the binding of a ligand d
dat a distal site may bias the conformational equilibrium
toward a structure in which the active site is more r
cactive or less active. In the case of LacI, IPTG binding
favors a conformation that is incapable of DNA binding, b
tlowering affinity for the operator by three orders of
magnitude. m
eThe work of Freire and others has shown that the two
binding sites of allosteric proteins typically differ in that
regulatory regions are of high flexibility, whereas active R
Msites usually maintain high stability in order to bind and
orient reactants productively [5]. Theoretical work sug-igure 1. Two Strategies for Engineering Molecular Switches
he structure of the LacI dimer bound to the inducer IPTG is shown
69]. One approach to creating switches is altering ligand binding
pecificity to create proteins that respond to nonnatural inputs
boxed). A second approach is to alter the allosteric response to
igand binding; the oval highlights a region on the LacI structure
etween the IPTG binding site and DNA binding domains (not
hown). Mutations in this region have been identified genetically
hat reverse LacI response upon ligand binding [70].ests that a “pathway” of energetically coupled resi-
ues must exist between the two sites for the energy
f binding to an allosteric regulator to affect catalysis
6]. A molecular switch must therefore possess finely
uned thermodynamic properties that link small-mole-
ule binding with a change in protein function. Another
pproach to engineering molecular switches that will
e discussed below is to change the connectivity of the
wo binding sites in a switch. Alteration of the allosteric
onformational shift of a switch can result in different
esponses to a given input; for example, the effect of
igand binding can shift from repression to activation of
protein’s function (Figure 1).
Molecular switches can exert control over three
tages of gene expression: transcription, translation,
nd protein function. Transcriptional regulation offers
he potential to effect the widest change in protein
evels. Translational control with small molecules was
iscovered only recently, but appears to have interme-
iate properties of speed and breadth of regulation. Di-
ect regulation of protein function (posttranslational
ontrol) gives the most temporal precision, as ligand
inding is transduced directly into altered protein func-
ion. Below, we discuss examples of engineering small-
olecule-dependent genetic switches that operate at
ach of these three levels.
egulation of Transcription
ost organisms regulate gene expression primarilythrough altering messenger RNA levels. An important
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regulatory signal is amplified. Binding of a transcription
factor to one or several copies of the gene can gener-
ate many mRNAs and thousands of active protein
molecules. Of the three levels of regulation, transcrip-
tional control typically provides the widest range of re-
sponse. The price paid for this range is a relatively slow
response time; although the E. coli lac operon responds
to transcriptional activation in less than 10 min, some
mammalian genes require w24 hr for the level of active
protein to plateau.
According to the recruitment model of Ptashne and
Gann [7], transcription is regulated by sequence-spe-
cific DNA binding proteins that localize components of
transcriptional machinery to a gene. The majority of
eukaryotic transcription factors are modular in the
sense that the DNA binding and activation activities are
located in separate and distinct domains. We will dis-
cuss efforts to engineer DNA binding domains to have
ligand-dependent DNA binding activity, then efforts to
alter the specificity of natural allosteric activators, and,
lastly, approaches to engineering the interaction be-
tween the DNA binding and activation domains them-
selves.
Creating Small-Molecule-Dependent
DNA Binding Domains
Several researchers have developed directed-evolution
strategies for creating DNA binding proteins that bind
to arbitrarily chosen DNA sequences [8–11]. Zinc-finger
domains each bind to three base pairs of DNA and can
be fused together to recognize longer sites. Using
phage-displayed zinc finger libraries and in vitro DNA
binding selections, Barbas and coworkers [12] evolved
zinc fingers that bind to each individual GNN codon.
The fusion of DNA binding domains with nuclear recep-
tor ligand binding domains (LBDs) makes transcrip-
tional activation dependent on steroid hormones. The
combination of three-finger Zif268 proteins evolved
using phage display, the VP16 activation domain, and
the estrogen receptor LBD created transcriptional
switches that were activated in cells w500-fold upon
ligand binding [13]. These studies demonstrated that
the zinc-finger technology can be used to target pro-
moters in a ligand-regulated manner.
Barbas, Schultz, and coworkers engineered a natural
zinc-finger protein, Zif268, to bind to DNA only in the
presence of a small-molecule ligand [14]. His125 and
Phe116, which participate in zinc binding and hy-
drophobic packing, were mutated to Ala and Gly,
respectively (Figure 2). The resulting cavity around the
zinc ion abolished transcriptional activation. Screening
250 heterocyclic molecules for their ability to activate a
luciferase gene identified 2-(4#-quinoline)-benzimida-
zole (1) as a small molecule that increases gene activity
in this system by 18-fold. This small molecule likely fills
the hydrophobic cavity and provides another coordinat-
ing aromatic amine ligand for the zinc ion. The authors
show that ligand binding increases the affinity of the
mutant protein for its DNA recognition site in vitro by
16-fold. This strategy of generating cavities in a protein
and then screening small molecules to fill the cavity is
similar to the “bump-hole” approach that has been
used to alter ligand binding specificity [15, 16]. In this
case, however, the presence of the ligand stabilizes the
protein structure and restores DNA binding activity.Figure 2. Engineering a Ligand-Dependent DNA Binding Protein
Phe116 (red) was mutated to Gly and His125 (blue) to Ala in the
zinc-finger domain from Zif268 [14]. The small molecule 1 was iso-
lated from a screen and found to enhance DNA binding of the dou-
bly mutated Zif268 by 16-fold.An impressive set of experiments by Hillen and co-
workers on the tetracycline repressor (TetR) represents
a second example of engineered ligand-dependent
DNA binding. TetR represses expression of the tetracy-
cline resistance protein TetA, which pumps tetracycline
out of the cell [17]. Overexpression of TetA is toxic to
bacteria, and TetR has evolved very high affinity for its
operator site (Kd = 10−14 M) to prevent TetA expression.
Because TetR must bind tetracycline and allow expres-
sion of the resistance protein before the antibiotic
reaches levels that inhibit translation, TetR has evolved
tight tetracycline binding (Kd = 10−9 M). Upon binding
tetracycline, the repressor loses affinity for the op-
erator.
Researchers attempting to develop orthogonal regu-
latory systems in eukaryotic cells have taken advan-
tage of TetR’s remarkable properties. Fusion of an acti-
vation domain to TetR created a hybrid transcription
factor regulated by tetracycline in mammalian cells
[18]. This tetracycline transcriptional activator (tTA)
binds DNA and activates transcription only in the ab-
sence of tetracycline; removal of the ligand from the
media was shown to increase expression of a luciferase
reporter gene by five orders of magnitude. This system
has been used in many contexts ranging in complexity
from yeast cells to mice (Figure 3) [19].
One practical drawback of the tTA system is that tet-
racycline must be present to keep gene expression re-
pressed, and ligand removal yields slower responses
than ligand addition. To address these issues, Hillen
and coworkers used a directed evolution approach to
create TetR mutants that only bind the operator in the
presence of tetracycline or its close analog doxycycline
[20]. The researchers developed a selection in E. coli in
which the functional DNA binding of TetR leads to sur-
vival and LacZ activity through the repression of a
repressor [21]. Selection for reversed TetR function
yielded proteins that remain bound to DNA in the pres-
ence of a nontoxic tetracycline analog. In the wild-type
TetR, ligand binding induces β-turn formation at the end
of helix 6, resulting in a 3 Å translation of the N-terminal
helices and preventing interaction with the major groove
of DNA. Mutations at positions 101 and 102 map to resi-
dues in this critical β turn and prevent ligand binding
from reducing DNA binding affinity [22]. Not only must
these mutations be compatible with the DNA-bound
conformation, but they also must alter the conforma-
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(A) The wild-type TetR protein binds to its operator site and re- e
presses expression of the tetA gene. Upon tetracycline (Tc) binding,
the receptor dissociates from DNA and tetA is expressed.
a(B) TetR fused to the VP16 activation domain (tTA, red) activates
eeukaryotic gene expression in the absence but not in the presence
4of tetracycline. The reverse TetR activator (rtTA, yellow) evolved by
Hillen [20] activates transcription only in the presence of tetracy- t
cline. m
i
ktional equilibrium to ensure that ligand binding is re-
nquired to assume that conformation. In a follow-up
Fstudy, the authors show that even single mutations in
rTetR can convey the reverse phenotype [23]. The di-
trected evolution approach was successful despite the
fheavily disfavored thermodynamics of the starting ma-
dterials: unliganded wild-type TetR has a 109-fold higher
taffinity for DNA than the liganded receptor. This experi-
mment is an example of the evolution of a novel coopera-
5tive linkage between two binding sites (one for tetracy-
g
cline and one for DNA) that yields a switch with
c
altered functionality.
t
Fusion of the VP16 activation domain to this novel
DNA binding domain generated the reverse tetracycline n
transcriptional activator (rtTA), which activates tran- f
scription only when induced by the addition of tetracy- a
cline analogs (Figure 3). In some applications, it was a
noted that the rtTA system exhibited a low-level back- s
ground activity in the absence of doxycycline and low c
sensitivity to induction. To address these problems, Hil- t
len and coworkers set up a second selection for re- t
versed TetR function, this time based on transcriptional s
activation in S. cerevisiae [24]. One clone exhibited 10- s
fold lower unliganded background and a second showed f
10-fold higher response to doxycycline induction than e
the original rtTA. These studies collectively imply the p
existence of a surprisingly large number of solutions in r
sequence space to the functional reversal of TetR. In
addition, they highlight the power of molecular evolu- a
tion approaches to generate and optimize protein con- t
formational changes induced upon ligand binding. d
Creating Orthogonal Transcriptional y
Activation Domains m
In contrast to these studies that alter DNA binding do- v
mains, the majority of efforts to create small-molecule- s
dependent transcriptional switches alter the ligand g
specificity of natural allosteric activation domains. This c
tapproach has been highly successful with the nuclearormone receptor family, generating orthogonal recep-
or-ligand pairs that have been used extensively to con-
rol eukaryotic gene expression.
The fact that small-molecule derivatives of NR li-
ands can be readily accessed by organic synthesis
akes these natural allosteric transcriptional switches
ttractive targets for engineering. Apart from their use
n regulating transcription, it has been shown that fu-
ion of steroid receptor ligand binding domains to sev-
ral classes of proteins renders the target protein hor-
one dependent [25]. Fusion to recombinases and
inases involved with cellular signaling (such as Src or
af) inhibits macromolecular association of the target
rotein and its substrates. This inhibition arises from
teric occlusion by the Hsp90 chaperone complex
ound to unliganded LBDs [25]. Hormone binding in-
uces a conformational shift, dissociation of the chap-
rone complex, and activation of target protein function.
One of the most widely used orthogonal mutants of
steroid receptor LBD is the Gly521Arg mutant of the
strogen receptor [known as ER(T)] that is induced with
-hydroxytamoxifen (4-OHT) but does not respond to
he natural hormone β-estradiol (Figure 4C) [26]. This
utation in the human ER-LBD was characterized dur-
ng a rational site-directed mutagenesis study by Par-
er and coworkers aimed at elucidating the determi-
ants of ER dimerization and ligand binding [27, 28].
urther analysis showed that the Gly521Arg mutation
educes affinity of the receptor for β-estradiol by more
han four orders of magnitude yet reduces the affinity
or 4-OHT by only 10-fold [29]. Analysis of the β-estra-
iol-bound [30] and 4-OHT-bound [31] crystal struc-
ures of the ER-LBD reveals how this altered specificity
ay be achieved (Figure 4). The side chain of residue
21 protrudes into the ligand binding pocket, and the
reater steric bulk of an arginine side chain reduces the
avity size. 4-OHT may be less affected by this change
han β-estradiol, which binds farther into the cavity.
Several groups have reported structure-based ratio-
al design strategies that remodel hydrophobic inter-
aces or alter charges in the active site of the retinoic
cid receptor or estrogen receptor (for a review see [32]
nd [33]). In general, remodeling of the binding site
hape has been more successful than attempts to re-
onfigure hydrogen-bonding patterns or ionic interac-
ions. As nuclear hormone receptors are further charac-
erized at the biochemical and structural levels, design
trategies to alter the ligand specificity of natural allo-
teric transcription factors may prove increasingly fruit-
ul. The use of structural information to inform directed
volution approaches has proven to be a particularly
owerful strategy in altering the ligand specificity of the
etinoic X receptor [34].
The above examples altered the specificity of natural
ctivation domains. In contrast, we recently reported
he creation de novo of an artificial allosteric activation
omain made of RNA [35]. Using a genetic selection in
east, we tethered random RNA sequences to a pro-
oter and identified a short RNA sequence that acti-
ates transcription with potency rivaling some of the
trongest natural protein activation domains [36]. Muta-
enesis and secondary structure prediction identified
rucial sequence and structural elements. Guided by
his information, we designed an insertion site to ac-
Review
155Figure 4. Estradiol and 4-OHT Binding Modes
The structure of the estrogen receptor bound to β-estradiol (A) shows the ligand bound deeply in a hydrophobic cleft [30]. Modeling of the
mutation Gly521Arg (red spheres) in the 4-OHT-bound structure (B) shows how the Arg side chain partially fills the ligand binding pocket and
shows the shallower binding of 4-OHT [31]. The structures of the ligands are depicted in (C).commodate a short RNA sequence previously selected
to bind the small-molecule dye tetramethylrosamine
(TMR) [37]. Screening and selection of a library of linker
sequences optimized a conformational shift in the RNA
activator, such that transcription is 10-fold higher in the
presence of TMR [35]. Although the resulting allosteric
RNA-based activators are less responsive to ligand
than typical protein transcriptional factors, these studies
demonstrate the strengths of RNA evolution and design
methods to create an allosteric linkage between a li-
gand binding and functional domain.
Regulation of Domain Interaction
Rather than engineer individual domains of transcrip-
tion factors to be regulated by nonnatural small mole-
cules, the highly successful “chemical inducer of di-
merization” (CID) strategy pioneered by Schreiber and
Clackson creates molecular switches by taking advan-
tage of the modular nature of eukaryotic transcription
factors [38]. According to the simple recruitment model
of transcription described above, there is no strict
requirement for transcription factor domains to be co-
valently fused. Association of the domains through pro-
tein-protein interactions, for example, is sufficient to re-
store robust transcriptional activation.
Two separate protein components comprise the orig-
inal CID strategy: a DNA binding domain (DBD) and an
activation domain (AD), each fused to a small molecule
binding domain [38, 39]. In the presence of an appropri-
ate dimeric small molecule (a “dimerizer”), both fusion
proteins bind the small molecule, recruiting the activa-
tion domain to the promoter of interest (Figure 5). The
most widely used chemical dimerizer system is based
on the small molecule binding domains FKBP and
FRAP, which bind to the small molecule rapamycin. Gil-
man and coworkers fused the FRB (FKBP and rapa-
mycin binding) domain of FRAP to the transcriptional
activator from NF-κB to create one hybrid protein and
fused a zinc-finger DNA binding domain to FKBP to
serve as the second [40]. Transcriptional induction of
R10,000-fold in the presence of rapamycin has been
achieved using this system in mammalian cells [40].
The nature of the components of the CID strategy
offer benefits compared with the previously described
approaches to allosteric transcription factors. SmallThey consist of two domains: an aptamer region that
Figure 5. Chemical Inducer of Dimerization Strategy to Control
Transcription
(A) In the absence of inducer, the split DNA binding and activation
domains of a transcription factor do not interact.
(B) Upon addition of a chemical dimerizer, the small-molecule bind-
ing domains (red and yellow) colocalize the DNA binding domain
and activation domain, resulting in transcription of a gene of in-
terest.molecules that resemble rapamycin can be synthesized
that interfere with dimerization by competition for one
of the drug binding domains, providing a rapid way to
shut a signal off. In addition, this approach offers very
low background signal in the absence of dimerizer, be-
cause the split transcription factor domains and the
drug binding domains have no instrinsic affinity for
each other. A third advantage is the modularity of the
system. Since signaling depends only on induced prox-
imity, each of the domains can be substituted to
achieve different DNA binding, activation, or repression
functions. This modularity raises the possibility of using
several orthogonal dimerizer systems in the cell to reg-
ulate separate genes of interest simultaneously [38].
Translational Control
Recent work by Breaker and coworkers has led to the
discovery of RNA-mediated small-molecule regulation
of translation. Termed “riboswitches,” these natural
translational switches are found in the 5#-untranslated
region (5#-UTR) of mRNAs of many prokaryotes [41].
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ithat interacts with regulatory elements in the mRNA,
such as the Shine-Dalgarno sequence. The aptamer β
mdomains are usually 70–170 nucleotides long and bind
their cognate ligands with low nanomolar to low micro- t
amolar dissociation constants. In one well-characterized
riboswitch [42], the binding of thiamine pyrophosphate a
c(TPP) blocks translational initiation by up to 16-fold in
several genes involved with thiamine biosynthesis in t
tE. coli. Riboswitches responsive to lysine, the nucleo-
bases, coenzyme B12, S-adenosylmethionine, and fla-
tvins have been characterized [41]. The scope of this
regulation is surprising: over 70 genes in B. subtilis (ap- a
tproximately 2% of the genome) are under the control
of riboswitches. The presence and conservation of ri- m
tboswitches in many species of bacteria suggest that
they may be primitive genetic regulatory elements that t
ahave not been replaced by protein-based machinery.
Researchers have shown that the principles of trans- c
llational control seen in many natural riboswitches can
be applied to the creation of artificial genetic switches. u
s(Indeed, natural riboswitches were discovered after re-
searchers had created similar switches in the labora- t
tory; see the work of Green below.) The generation of
RNA sequences that bind molecules not involved in l
scellular metabolism relies on in vitro evolution tech-
niques. Over the last 15 years, it has been shown that u
oRNAs can be isolated from large random libraries to
bind many disparate small-molecule and macromole- f
scule targets [43]. These RNAs, known as aptamers, can
be inserted into the 5#-UTR of a gene of interest in such m
ta way as to regulate transcriptional initiation. This step
in gene expression varies in mechanism between pro- o
rkaryotes and eukaryotes; two distinct approaches have
therefore been developed. c
In prokaryotes, occlusion of the ribosome binding
site prevents translational initiation. It is thought that s
ssome natural riboswitches form RNA secondary struc-
tures that prevent ribosome binding. As ligand binding d
Mtypically stabilizes these structures, most riboswitches
act as repressors of translation in the presence of li- c
tgand. In a recent study, Hillen and coworkers designed
an artificial riboswitch that acts as an activator, increas- l
ging translation 8-fold upon the addition of theophylline
[44]. This study made use of an RNA aptamer for theo- i
sphylline [45] and a structural bridge previously evolved
by Soukup and Breaker [46]. Upon ligand binding, a m
econformational change occurs and the double-stranded
structural bridge slips by one base (Figure 6). Guided U
fby secondary structure prediction programs, Hillen de-
signed an inhibiting structure that frees one extra base d
Mnear the Shine-Dalgarno sequence upon theophylline
binding, allowing initiation of translation. This example w
adiffers from most riboswitches in that the sense of reg-
ulation is reversed; addition of ligand activates, rather [
pthan represses, gene expression.
In contrast to the simpler mechanism of prokaryotic s
translational initiation, the eukaryotic ribosomal ma-
chinery recognizes the cap structure at the 5# end of s
tmRNA and scans until it forms the initiation complex at
the first AUG codon. This scanning process is known z
eto be inhibited by the binding of natural proteins (such
as the iron response protein acting on the ferritin i
rmRNA) [47]. In 1998, Green and coworkers reported theelection of aptamers to a small-molecule dye and the
nsertion of two such sequences into the 5#-UTR of a
-galactosidase reporter gene. Gene expression in
ammalian cells decreased 10-fold in the presence of
he ligand [48]. This pioneering study showed that RNA
ptamers evolved in vitro can bind their ligands tightly
nd specifically in vivo (Figure 6) and that small-mole-
ule binding can structure the 5#-UTR in such a way as
o prohibit eukaryotic translational initiation, probably
hrough the inhibition of ribosome scanning.
A similar mechanism of action led to inhibition of
ranslation in S. cerevisiae in work reported by Wilson
nd coworkers [49]. The researchers inserted an ap-
amer previously selected in vitro to bind the small
olecule tetramethylrosamine (TMR) into the 5#-UTR of
he CLB2 cyclin gene. TMR inhibited Clb2 translation in
his system 10-fold. A phenotype of cell-cycle slowing
nd elongated cellular morphology was also observed,
onfirming that this methodology can alter natural bio-
ogical function and serve as a genetic tool [49]. The
se of aptamers to inhibit translational initiation is
omewhat limited by the fact that repression greater
han 10-fold has not yet been reported.
Rather than blocking the initiation of translation, Mul-
igan and coworkers have developed a strategy to de-
troy mRNA in a ligand-dependent manner through the
se of self-cleaving ribozymes [50]. Screening a number
f natural and engineered ribozymes for activity in vivo
ollowed by optimization identified a mutant Schisto-
oma monsoni hammerhead ribozyme that is active in
ammalian cells. The difficulty in finding a ribozyme
hat functions in living cells underscores an advantage
f developing genetic switches in vivo: namely, that the
esulting switch naturally functions in the desired
ontext.
When inserted into a reporter mRNA immediately up-
tream of translational start, the optimized ribozyme
elf-cleaves before translation can occur, resulting in
egradation of the mRNA and loss of gene expression.
ulligan and coworkers screened w50,000 small mole-
ules with in vivo assays to find a small-molecule ligand
hat inhibited ribozyme cleavage. The nucleoside ana-
og toyocamycin inhibited mRNA cleavage and restored
ene expression roughly 250-fold (for comparison, an
nactive ribozyme restored expression 3000-fold). In-
ertion of a ribozyme-luciferase vector into a mouse
odel showed 40- to 190-fold induction of luciferase
xpression in the retina upon toyocamyin addition [50].
npublished experiments reveal that toyocamycin may
unction by incorporation into the mRNA, rather than
irect binding and inhibition of ribozyme function (R.
ulligan, personal communication). When combined
ith evolution-based technologies that allow the cre-
tion of small-molecule-dependent ribozyme function
51] and other RNA engineering tools [52], it may be
ossible to engineer similar ribozymes to respond to
mall-molecule inducers of choice.
In summary, recent studies have shown that natural
mall-molecule binding aptamers can act as riboswitches
o inhibit translation [41] or, when combined with ribo-
ymes, can induce RNA cleavage [53] in bacteria. Sev-
ral reports have shown that evolved aptamers can be
nserted into the 5#-UTR of eukaryotic mRNAs to block
ibosome scanning and initiation, or into prokaryotic
Review
157Figure 6. Structure of Aptamers and Ligands
Used in Engineering Translational ControlmRNAs to block ribosome binding, though the breadth
of regulation is somewhat limited. Ligand-dependent ri-
bozymes have also been shown to destroy mRNA and
effect regulation of gene expression in mammalian cells
at levels that rival transcriptional control elements.
These strategies do not require specialized promoters
or separate regulatory proteins and greatly increase the
number of inducers that can be used. Although the de-
velopment of RNA-based translational switches is still
in its infancy, this approach may yield faster respon-
ses than transcriptional regulation, especially in eu-
karyotes.
Direct Regulation of Protein Function
Posttranslational regulation of protein function can pro-
vide high temporal precision and is frequently used in
natural systems to rapidly modulate protein activities.
While binding of a small-molecule inhibitor to a protein
target can exert an immediate effect, this direct regula-
tion of protein function suffers from a lack of generality.
Whereas a single genetic switch can regulate transcrip-
tion or translation of an arbitrary gene of interest, small
molecule-protein interactions are usually specific to a
single protein target. The synthesis and identification of
potent and selective inhibitors or activators for a target
protein remain significant challenges despite improve-
ments in synthesis and screening methods. Two strate-
gies have recently emerged to generate genetic switches
that combine generality with the rapid kinetics and
dose dependence that are characteristic of small-mole-
cule control of protein function.
Regulation of Protein Localization and Degradation
The first strategy has already been previewed above
and consists of controlling protein localization with
chemical inducers of dimerization. The colocalization
of catalytic activities and substrates through protein-
protein interactions is one of the major mechanisms of
enforcing specificity in signaling pathways. In the early
1990s, two natural small molecules, FK506 and rapa-mycin, were found to dimerize proteins in vivo. FK506
binds to a small monomeric protein known as FKBP
and also binds to and inhibits calcineurin. Rapamycin
also pairs with FKBP, using a chemical substructure
similar to that of FK506, but complexes and inhibits a
protein known as FRAP (FKBP-rapamycin associated
protein) [16]. It was soon recognized by Schreiber,
Crabtree, and coworkers that these natural systems
could be generalized into a method to control biological
function with small-molecule dimerizers of proteins.
The first protein function artificially regulated using
chemical dimerizers was signaling by the T cell antigen
receptor (TCR) [54]. The signaling domain of the TCR
was fused with FKBP to confer the ability to bind FK506
analogs. A semisynthetic FK506 dimer was prepared
that binds FKBP but not calcineurin. The addition of the
FK506 dimer oligomerized the signaling domain-FKBP
fusions, activating a reporter gene downstream of the
signaling pathway. The chemical dimerization strategy
developed by Schreiber, Crabtree, and coworkers in-
duces a protein-protein interaction. Chemical inducers
of dimerization have proven to be effective for con-
trolling the function of membrane receptors, protein ki-
nases, and death domains, as well as transcription
factors as described in the first section (for a list of
dimerizer references, see http://www.ariad.com/regula-
tionkits/reg_ref1.html). If the logic of induced proximity
can control a protein function of interest, this strategy
can be used to create small-molecule-dependent
switches that act rapidly and with tunable potency.
One shortcoming of the use of the natural immu-
nophilin ligands is that their binding proteins are en-
dogenously expressed at high levels in many cells.
Clackson and coworkers attempted to solve this speci-
ficity problem (for a review see [16]) through the cre-
ation of an orthogonal dimerizer-FKBP pair using the
“bump-hole” approach. The addition of an ethyl group
“bump” effectively destroyed the ability of a known
synthetic ligand to bind to wild-type FKBP [55]. Analy-
sis of the cocrystal structure and modeling studies pre-
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Splicing Strategiesdicted that mutation of Phe36 of FKBP to a smaller resi- a
tdue (creating a “hole”) would accommodate the larger
ligand. The synthetic ligand AP1903 binds to the FKBP e
PPhe36Val mutant with affinity comparable to that of
wild-type FK506 for wild-type FKBP, but with 1000-fold g
Hspecificity for the FKBP mutant [55].
The synthetic dimerizers described above are both g
thomodimers, precluding their use in predictably forcing
the interaction of two different FKBP-fusion proteins. c
sThe natural heterodimerizer rapamycin has good phar-
macokinetic properties and binds both FKBP and the s
aFRB domain of FRAP. Schreiber and coworkers re-
ported the synthesis of a bumped rapamycin analog b
w[56] which interacts only with a mutant FRB that was
identified through mutagenesis and selection; this li- i
tgand-receptor pair is fully orthogonal to cellular systems.
In the course of their work to develop the orthogonal k
tFKBP described above, Clackson and coworkers iden-
tified a mutation (Phe36Met) that reverses the ligand a
tdependence of FKBP dimerization. This mutant FKBP
forms discrete dimers that dissociate upon ligand bind- S
Ting [57]. Such a switch can shut off activities that are
induced by proximity or turn on activities that are re- s
npressed by oligomerization. These “conditional aggre-
gation domains” act rapidly; in one example, large ag- s
wgregates of GFP were created and dissolved in vivo
within minutes. In a further study, multimers of the t
oPhe36Met FKBP mutant were used to aggregate insulin
in the endoplasmic reticulum, preventing secretion [58]. d
gRapid and transient secretion was observed following
treatment with the ligand in a mouse model. s
pA promising new application of the dimerization strat-
egy provides small-molecule-mediated control of pro- t
btein degradation. Rather than creating small molecules
that inhibit protein function, Crews and coworkers have t
developed chemical inducers of dimerization that re-
cruit the proteosome to a protein target, in effect gener- d
pating a “chemical knockout” [59, 60]. Proteins are
marked for degradation upon the covalent attachment i
hof ubiquitin by a class of proteins known as the E3 li-
gases. Using a dimerization strategy, Crews and co- a
Tworkers effectively redirected the substrate specificity
of these enzymes and made the process ligand de- s
spendent.
The dimerizer ligands (termed proteolysis targeting b
7chimeric molecules, or “PROTACS”) consist of a small-
molecule-based ligand for the protein target covalently t
Nlinked to a short amino acid sequence recognized byn endogenous E3 ligase. The dimerizer is also at-
ached to a poly-D-arginine tag at the C terminus to
nhance cell permeability [61]. In one example, the
he36Val mutant of FKBP described above was fused
enetically to the green fluorescent protein (GFP) in
eLa cells [59]. A dimerizer consisting of an FKBP li-
and similar to AP1903 and the peptide-based E3
argeting element induced a dramatic loss of fluores-
ence due to degradation of the GFP-FKBP protein. Fu-
ion of a target of interest to a ligand binding protein
uch as FKBP may make this approach general for any
rbitrary target. Proteins with natural small molecule
inding sites, such as steroid receptors, can be targeted
ithout any genetic manipulation simply by synthesiz-
ng dimerizers containing their natural ligands [59]. Al-
hough the generality, level of regulation, and detailed
inetics of the PROTACS approach are not yet known,
his novel application of the dimerization system may
llow small-molecule control over the important regula-
ory step of protein degradation.
mall-Molecule-Dependent Protein Splicing
he second strategy for engineering ligand-dependent
witches that act posttranslationally is based on the
atural process of protein splicing. Inteins are self-
plicing protein elements, analogous to introns in RNA,
hich catalyze their excision from within a larger pro-
ein context (called the N- and C-exteins) [62]. Insertion
f an intein into a protein target of interest typically ren-
ers the target protein inactive until splicing occurs. Li-
and-dependent inteins represent attractive molecular
witches because protein splicing occurs in almost any
rotein context and is rapid compared with transcrip-
ion and translation. Natural inteins are not regulated
y small-molecule ligands, however; splicing begins to
ake place immediately upon translation.
Two distinct approaches to the creation of ligand-
ependent protein-splicing elements have been re-
orted. In a phenomenon known as trans-splicing, an
ntein can be split into inactive N- and C-terminal
alves; when combined, these halves can reconstitute
n active intein structure fully capable of splicing [63].
aking advantage of the dimerization strategy de-
cribed above, Mootz and Muir developed a trans-
plicing system in which the two intein fragments are
rought together by the addition of rapamycin (Figure
) [64]. The S. cerevisiae VMA intein was split such that
he halves had very low affinity for one another. The
-terminal intein was fused to MBP (as an extein) and
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and a His6 tag. Binding of rapamycin to FKBP and FRB
colocalizes the intein fragments, which then fold to-
gether correctly and splice, yielding an MBP-His6 pro-
duct. The authors show that splicing occurs in vitro
only in the presence of rapamycin and that splicing is
rapid, with 50% splicing after roughly 60 min.
In a further study, Muir and coworkers reported suc-
cessful conditional trans-splicing in mammalian cells
[65]. Formation of the MBP-His6 product occurred in
vivo solely in the presence of rapamycin, with product
visible after only 10 min. Splicing was shown to be tun-
able over a wide dynamic range depending on the
amount of ligand added. The authors also showed that
the splicing reaction could be stopped by addition of a
competitor ligand that binds FKBP but does not recruit
FRB. It should be noted that one characteristic of in-
tein-based switches is that the splicing reaction is
irreversible; once the intein is excised and the target
protein is formed, it will be present until naturally de-
graded. In contrast, the original CID system can be shut
off rapidly by addition of a competitive ligand because
only protein localization and not synthesis and degra-
dation is being regulated.
A second approach to the creation of ligand-depen-
dent inteins relies on allosteric control of intein splicing
rather than localization of split-intein halves. Since in-
teins do not naturally bind small molecules, we inserted
the estrogen receptor ligand binding domain (LBD) be-
tween the halves of the intein, creating an intein-ER fu-
sion that is incapable of splicing [66]. Using genetic se-
lections in S. cerevisiae, we evolved intein-ER mutants
capable of splicing. The ligand dependence of the re-
sulting intein mutants was greatly improved by screen-
ing yeast cells expressing mutant intein-ER libraries in-
serted into GFP (Figure 7). Such “negative screening”
against protein function in the absence of ligand is an
important directed evolution tool when a high degree
of ligand dependence is desirable.
After three rounds of mutagenesis, selection, and
screening, we identified intein-ER mutants that exhibit
excellent ligand dependence in yeast cells, only splic-
ing in the presence of 4-OHT. The evolved switch acts
at a posttranslational level, and spliced product ap-
pears within 30 min of exposure to ligand. When 4-OHT
concentrations are varied across a wide range, the
evolved intein exhibits a graded dose dependence. In-
sertion of one evolved intein into four different protein
contexts (KanR, GFP, the endogenous yeast Ade2 pro-
tein, and LacZ) rendered each of these protein targets
inactive until the inducer was added, demonstrating the
generality of this switch. While early in the stages of
development and application, both of these small-
molecule-dependent intein strategies may serve as
powerful and general tools to control protein function
directly with small molecules.
Conclusions
Research in the area of small-molecule-dependent ge-
netic switches has produced a number of mechanistic
insights and powerful tools for use in genetics, cell biol-
ogy, and gene therapy. Three common strategies have
emerged for creating artificial molecular switches thatcontrol biological function in response to exogenous
small-molecule ligands. The first strategy modifies the
ligand binding specificity of a natural switch to recog-
nize a nonnatural ligand. This strategy requires the syn-
thesis of analogs of the small-molecule effector and
engineering or evolution of its protein partner to create
an orthogonal ligand-receptor pair. In addition to nuclear
receptor ligand binding domains [67] and immunophi-
lins [56], the tetracycline repressor (TetR) has been al-
tered using directed evolution approaches to recognize
new ligands [68]. The introduction of screens or selec-
tions against binding of the natural ligand may further
enhance the ability of evolutionary approaches to cre-
ate truly altered, rather than broadened, specificity.
The second strategy for creating small-molecule-
dependent switches is to regulate protein activity through
the colocalization of modular functional domains.
Chemical inducers of dimerization were shown to acti-
vate transcription through induced proximity of DNA
binding and activation domains [38, 39]. The dimerizer
strategy is also capable of direct regulation of protein
activity, for example, activating signaling pathways
through the colocalization of kinases and their sub-
strates [54] or targeting the proteosome machinery to
a protein target [59]. When this approach is applied to
fragments of a target protein fused to trans-splicing
systems, a small molecule can trigger the covalent as-
sembly of the intact protein together with the concom-
mitant loss of the dimerization and intein domains [65].
The third strategy is to engineer allosteric regulation,
manipulating a conformational change induced by li-
gand binding to create a novel downstream protein or
RNA function. The evolution of a reversed allosteric re-
sponse in the TetR protein [20] and the engineering of
ligand binding sites in a DNA binding domain [14] are
examples of engineered allosteric regulation of protein
function with small molecules. Similarly, small-molecule
aptamers evolved in vitro can be inserted into the 5#-
UTR of mRNAs to effect a conformational shift in the
RNA upon ligand binding that regulates translational
initiation in prokaryotes [44] and eukaryotes [48]. Our
studies combining functional and ligand binding do-
mains, in both RNA-based transcription factors [35]
and inteins [66], underscore the ability of directed evo-
lution to create strong linkages between unrelated do-
mains. We anticipate that directed evolution approaches
will play an increasingly important role in creating
small-molecule-dependent genetic switches for the
study and control of biological systems.
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